Проблемы клеточной терапии и стволовых клеток
https://doi.org/10.18699/SSMJ20210101
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Полный текст:
Аннотация
Стволовые клетки и клеточная терапия – одна из самых широко обсуждаемых тем в медико-биологической литературе. Предполагается дифференцировка стволовых клеток в направлении специализированных тканей, замещение поврежденных и стареющих клеточных элементов. Однако дифференцировка in vitro с экспрессией маркеров еще не доказывает замещение специализированных клеток in vivo. В данной статье обсуждается клеточная терапия при заболеваниях сердца, печени, суставов, центральной нервной системы, а также при сахарном диабете. Приведены недавние сведения по ее применению при COVID-19. Многие публикации преувеличивают эффективность клеточной терапии и не уделяют достаточного внимания побочным эффектам. В глобальном масштабе отмечается рост числа клиник, предлагающих данный способ лечения. В заключение, методы терапии с недоказанной эффективностью и возможными побочными эффектами должны применяться в рамках научных исследований высокого качественного уровня, свободных от конфликта интересов.
Об авторе
С. В. Яргин
Российский университет дружбы народов
Россия
Россия
Сергей Вадимович Яргин, к.м.н.
117198, г. Москва, ул. Миклухо-Маклая, 6
Список литературы
1. Jargin S.V. Scientific papers and patents on substances with unproven effects. Part 2. Recent Pat. Drug Deliv. Formul. 2019; 13 (3): 160-173. https://doi.org/10.2174/1872211313666190819124752
2. Lau A., Kennedy B.K., Kirkland J.L., Tullius S.G. Mixing old and young: enhancing rejuvenation and accelerating aging. J. Clin. Invest. 2019; 129 (1): 4-11. https://doi.org/10.1172/JCI123946
3. Nguyen N., Sussman M.A. Rejuvenating the senescent heart. Curr. Opin. Cardiol. 2015; 30 (3): 235-239. https://doi.org/10.1097/HCO.0000000000000161
4. Neves J., Sousa-Victor P., Jasper H. Rejuvenating strategies for stem cell-based therapies in aging. Cell Stem Cell. 2017; 20 (2): 161-175. https://doi.org/10.1016/j.stem.2017.01.008
5. Zakrzewski W., Dobrzyński M., Szymonowicz M., Rybak Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 2019; 10: 68. https://doi.org/10.1186/s13287-019-1165-5
6. Blum B., Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009; 8 (23): 3822-3830. https://doi.org/10.4161/cc.8.23.10067
7. Lee H.Y., Hong I.S. Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential. Cancer Sci. 2017; 108 (10): 19391946. https://doi.org/10.1111/cas.13334
8. Amariglio N., Hirshberg A., Scheithauer B.W., Cohen Y., Loewenthal R., Trakhtenbrot L., Paz N., Koren-Michowitz M., Waldman D., Leider-Trejo L., Toren A., Constantini S., Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009; 6: e1000029. https://doi.org/10.1371/journal.pmed.1000029
9. Dlouhy B.J., Awe O., Rao R.C., Kirby P.A., Hitchon P.W. Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient: Case report. J. Neurosurg. Spine. 2014; 21 (4): 618-622. https://doi.org/10.3171/2014.5.SPINE13992
10. Berkowitz A.L., Miller M.B., Mir S.A., Cagney D., Chavakula V., Guleria I., Aizer A., Ligon K.L., Chi J.H. Glioproliferative lesion of the spinal cord as a complication of «stem-cell tourism». N. Engl. J. Med. 2016; 375 (2): 196-198. https://doi.org/10.1056/NEJMc1600188
11. Анисимов С.В. Клеточная терапия болезни Паркинсона. СПб.: Н.-Л., 2014. 320 c.
12. Deblandre G.A., Scheers I., Sokal E.M. Stemand progenitor cells for liver regenerative medicine. In: Regenerative medicine and cell therapy. Ed. J.-F. Stoltz. Amsterdam: IOS Press, 2012; 390-402.
13. Ciervo Y., Ning K., Jun X., Shaw P.J., Mead R.J. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. Mol. Neurodegener. 2017; 12 (1): 85. https://doi.org/10.1186/s13024-0170227-3
14. Jevotovsky D.S., Alfonso A.R., Einhorn T.A., Chiu E.S. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthritis Cartilage. 2018; 26: 711-729. https://doi.org/10.1016/j.joca.2018.02.906
15. Herberts C., Kwa M., Hermsen H. Risk factors in the development of stem cell therapy. J. Transl. Med. 2011; 9: 29. https://doi.org/10.1186/1479-5876-9-29
16. Carotenuto F., Teodori L., Maccari A.M., Delbono M.L., Orlando G., di Nardo P. Turning regenerative technologies into treatment to repair myocardial injuries. J. Cell. Mol. Med. 2020; 24 (5): 2704-2716. https://doi.org/10.1111/jcmm.14630
17. Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: A fundamental biosafety aspect. Int. J. Mol. Sci. 2019; 20 (10): 2406. https://doi.org/10.3390/ijms20102406
18. Яргин С.В. Стволовые клетки и клеточная терапия: на подступах к научному подходу. Цитология. 2010; 52 (11): 918-920.
19. Marsh S.E., Blurton-Jones M. Neural stem cell therapy for neurodegenerative disorders: the role of neurotrophic support. Neurochem. Int. 2017; 106: 94-100. https://doi.org/10.1016/j.neuint.2017.02.006
20. Watanabe T.K. A review of stem cell therapy for acquired brain injuries and neurodegenerative central nervous system diseases. PM. R. 2018; 10 (9, Suppl. 2): 151-156. https://doi.org/10.1016/j.pmrj.2018.07.008
21. Ullah M., Sun Z. Stem cells and anti-aging genes: double-edged sword-do the same job of life extension. Stem Cell Res. Ther. 2018; 9: 3. https://doi.org/10.1186/s13287-017-0746-4
22. Terzic A., Behfar A. Posology for regenerative therapy. Circ. Res. 2017; 121: 1213-1215. https://doi.org/10.1161/CIRCRESAHA.117.312074
23. Elnakish M.T., Hassan F., Dakhlallah D., Marsh C.B., Alhaider I.A., Khan M. Mesenchymal stem cells for cardiac regeneration: translation to bedside reality. Stem Cells Int. 2012; 2012: 646038. https://doi.org/10.1155/2012/646038
24. Jaquet K., Krause K.T., Denschel J., Faessler P., Nauerz M., Geidel S., Boczor S., Lange C., Stute N., Zander A., Kuck K.-H. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism? Stem Cells Dev. 2005; 14 (3): 299-309. https://doi.org/10.1089/scd.2005.14.299
25. Le T., Chong J. Cardiac progenitor cells for heart repair. Cell Death Discov. 2016; 2: 16052. https://doi.org/10.1038/cddiscovery.2016.52
26. Suncion V.Y., Ghersin E., Fishman J.E., Zambrano J.P., Karantalis V., Mandel N., Nelson K.H., Gerstenblith G., DiFede Velazquez D.L., Breton E., Sitammagari K., Schulman I.H., Taldone S.N., Williams A.R., Sanina C., Johnston P.V., Brinker J., Altman P., Mushtaq M., Trachtenberg B., Mendizabal A.M., Tracy M., da Silva J., McNiece I.K., Lardo A.C., George R.T., Hare J.M., Heldman A.W. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ. Res. 2014; 114 (8): 1292-1301. https://doi.org/10.1161/CIRCRESAHA.114.302854
27. Martin-Rendon E., Brunskill S.J., Hyde C.J., Stanworth S.J., Mathur A., Watt S.M. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 2008; 29 (15): 18071818. https://doi.org/10.1093/eurheartj/ehn220
28. Wernly B., Mirna M., Rezar R., Prodinger C., Jung C., Podesser B.K., Kiss K., Hoppe U.C., Lichtenauer M. Regenerative cardiovascular therapies: stem cells and beyond. Int. J. Mol. Sci. 2019; 20: 1420. https://doi.org/10.3390/ijms20061420
29. Ghiroldi A., Piccoli M., Cirillo F. Monasky M.M., Ciconte G., Pappone C., Anastasia L. Cellbased therapies for cardiac regeneration: a comprehensive review of past and ongoing strategies. Int. J. Mol. Sci. 2018; 19: 3194. https://doi.org/10.3390/ijms19103194
30. Christ G.J., Andersson K.-E. Introduction to regenerative pharmacology. In: Regenerative pharmacology. Eds. G.J. Christ, K.-E. Andersson. Cambridge: Cambridge University Press, 2013; 3-15.
31. Nagy J.A., Dvorak A.M., Dvorak H.F. VEGF-A (164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc. Med. 2003; 13 (5): 169-175. https://doi.org/10.1016/s1050-1738(03)00056-2
32. Schaper W., Buschmann I. VEGF and therapeutic opportunities in cardiovascular diseases. Curr. Opin. Biotechnol. 1999; 10 (6): 541-543. https://doi.org/10.1016/s09581669(99)00032-4
33. Purdon S., Patete C.L., Glassberg M.K. Multipotent mesenchymal stromal cells for pulmonary fibrosis? Am. J. Med. Sci. 2019; 357: 390-393. https://doi.org/10.1016/j.amjms.2019.02.007
34. Bardelli S., Moccetti M. Stem and progenitor cells in human cardio-pulmonary development and regeneration. Stem Cells Int. 2017; 2017: 2653142. https://doi.org/10.1155/2017/2653142
35. Fisher S.A., Zhang H., Doree C., Mathur A., Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 2015; (9): CD006536. https://doi.org/10.1002/14651858.CD006536.pub4
36. Fisher S.A., Brunskill S.J., Doree C., Mathur A., Taggart D.P., Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst. Rev. 2016; (12): CD007888. https://doi.org/10.1002/14651858.CD007888.pub3
37. Toyserkani N.M., Jørgensen M.G., Tabatabaeifar S., Jensen C.H., Sheikh S.P., Sørensen J.A. Concise review: a safety assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events. Stem Cells Transl. Med. 2017; 6 (9): 1786-1794. https://doi.org/10.1002/sctm.17-0031
38. Editorial. A futile cycle in cell therapy. Should a cell therapy for heart disease with scant evidence of efficacy continue to be tested in humans? Nat. Biotechnol. 2017; 35 (4): 291. https://doi.org/10.1038/nbt.3857
39. Яргин С.В. Некоторые аспекты применения стволовых клеток в кардиологии. Цитология. 2019; 61 (6): 500-503. https://doi.org/10.1134/S0041377119060099
40. Шомина Е.А., Ярыгин Н.В., Ярыгин К.Н. Способ лечения ишемической ангиопатии сосудов нижних конечностей. Пат. РФ RU2649498C1; Опубл. 03.04.2018.
41. Николаенко Н.С. Восстановление хрящевой ткани с помощью клеточных технологий. В кн.: Клеточные технологии для регенеративной медицины. Ред. Г.П. Пинаев, М.С. Богданова, А.М. Кольцова. СПб.: Политехн. ун-т, 2011; 162-176.
42. Mancuso P., Raman S., Glynn A., Barry F., Murphy J.M. Mesenchymal stem cell therapy for osteoarthritis: The critical role of the cell secretome. Front. Bioeng. Biotechnol. 2019; 7: 9. https://doi.org/10.3389/fbioe.2019.00009
43. Castro-Viñuelas R., Sanjurjo-Rodríguez C., Piñeiro-Ramil M., Hermida-Gómez T., Fuentes-Boquete I.M., de Toro-Santos F.J., Blanco-García F.J., Díaz-Prado S.M. Induced pluripotent stem cells for cartilage repair: current status and future perspectives. Eur. Cell. Mater. 2018; 36: 96-109. https://doi.org/10.22203/eCM.v036a08
44. Jargin S.V. Supplementation of glycosaminoglycans and their precursors in osteoarthritis versus diet modification. Int. J. Rheum. Dis. 2012; 15 (3): 45-46. https://doi.org/10.1111/j.1756-185X.2012.01707.x
45. Rashid H., Kwoh C.K. Should platelet-rich plasma or stem cell therapy be used to treat osteoarthritis? Rheum. Dis. Clin. North Am. 2019; 45: 417-438. https://doi.org/10.1016/j.rdc.2019.04.010
46. Lukomska B., Stanaszek L., Zuba-Surma E., Legosz P., Sarzynska S., Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019; 2019: 9628536. https://doi.org/10.1155/2019/9628536
47. Kang S.H., Kim M.Y., Eom Y.W., Baik S.K. Mesenchymal stem cells for the treatment of liver disease: Present and perspectives. Gut Liver. 2020; 14 (3): 306-315. https://doi.org/10.5009/gnl18412
48. Guo Y., Chen B., Chen L.-J., Zhang C.-F., Xiang C. Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J. Zhejiang Univ. Sci. B. 2016; 17: 831-841. https://doi.org/10.1631/jzus.B1600101
49. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., Ganesan S., Glod J.W., Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008; 68 (11): 4331-4339. https://doi.org/10.1158/00085472.CAN-08-0943
50. Nicolas C., Wang Y., Luebke-Wheeler J., Nyberg S.L. Stem cell therapies for treatment of liver disease. Biomedicines. 2016; 4 (1): 2. https://doi.org/10.3390/biomedicines4010002
51. Rota C., Morigi M., Imberti B. Stem cell therapies in kidney diseases: progress and challenges. Int. J. Mol. Sci. 2019; 20 (11): 2790. https://doi.org/10.3390/ijms20112790
52. Donzelli E., Scuteri A. Mesenchymal stem cells: a trump card for the treatment of diabetes? Biomedicines. 2020; 8 (5): 112. https://doi.org/10.3390/biomedicines8050112
53. Shapiro A.M.J. Gearing up for stem cell-derived beta cells-are we ready? Transplantation. 2018; 102 (8): 1207-1208. https://doi.org/10.1097/TP.0000000000002214
54. van der Torren C.R., Zaldumbide A., Duinkerken G., Brand-Schaaf S.H., Peakman M., Stangé G., Martinson L., Kroon E., Brandon E.P., Pipeleers D., Roep B.O. Immunogenicity of human embryonic stem cell-derived beta cells. Diabetologia. 2017; 60 (1): 126-133. https://doi.org/10.1007/s00125-016-4125-y1
55. Van de Vyver M. Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy. Stem Cells Dev. 2017; 26 (14): 1042-1053. https://doi.org/10.1089/scd.2017.0025
56. Kornicka K., Houston J., Marycz K. Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev. Rep. 2018; 14 (3): 337-345. https://doi.org/10.1007/s12015-018-9809-x
57. Cheng S.K., Park E.Y., Pehar A., Rooney A.C., Gallicano G.I. Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus. Am. J. Stem Cells. 2016; 5 (3): 74-86.
58. Saldanha-Araujo F., Melgaço Garcez E., Silva-Carvalho A.E., Carvalho J.L. Mesenchymal stem cells: a new piece in the puzzle of COVID-19 treatment. Front. Immunol. 2020; 11: 1563. https://doi.org/10.3389/fimmu.2020.01563
59. FDA Warns About Stem Cell Therapies. Available at: https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
60. Turner L. Preying on public fears and anxieties in a pandemic: businesses selling unproven and unlicensed «stem cell treatments» for COVID-19. Cell Stem Cell. 2020; 26 6): 806-810. https://doi.org/10.1016/j.stem.2020.05.003
61. Kenmuir C.L., Wechsler L.R. Update on cell therapy for stroke. Stroke Vasc. Neurol. 2017; 2 (2): 59-64. https://doi.org/10.1136/svn-2017-000070
62. Xiao K., Hou F., Huang X., Li B., Qian Z.R., Xie L. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19. Stem Cell Res. Ther. 2020; 11 (1): 305. https://doi.org/10.1186/s13287-020-01804-6
63. Heslop J., Hammond T., Santeramo I., Hopp I., Zhou J., Baty R., Graziano E.I., Proto Marco B., Caron A., Sköld P., Andrews P.W., Baxter M.A., Hay D.C., Hamdam J., Sharpe M.E., Patel S., Jones D.R., Reinhardt J., Danen E.H.J., Ben-David U., Stacey G., Björquist P., Piner J., Mills J., Rowe C., Pellegrini G., Sethu S., Antoine D.J., Cross M.J., Murray P., Williams D.P., Kitteringham N.R., Goldring C.E.P., Park B.K. Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl. Med. 2015; 4 (4): 389-400. https://doi.org/10.5966/sctm.2014-0110
64. Bamba C., Singh S.P., Choudhury S. Can mesenchymal stem cell therapy be the interim management of COVID-19? Drug Discov. Ther. 2020; 14 (3): 139-142. https://doi.org/10.5582/ddt.2020.03032
65. Liang B., Chen J., Li T., Wu H., Yang W., Li Y., Li J., Yu C., Nie F., Ma Z., Yang M., Xiao M., Nie P., Gao Y., Qian C., Hu M. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020; 99 (31): e21429. https://doi.org/10.1097/MD.0000000000021429
66. Jargin S. Some aspects of stem cell therapy. Cyprus J. Med. Sci. 2020; 5 (2): 183-185. https://doi.org/10.5152/cjms.2020.812
67. Ревищин А.В., Павлова Г.В., Охотин В.Е., Яковлева К.А. Клеточная терапия при нейродегенеративных заболеваниях. М.: МПГУ, 2017. 160 c.
68. Willing A.E., Das M., Howell M., Mohapatra S.S., Mohapatra S. Potential of mesenchymal stem cells alone, or in combination, to treat traumatic brain injury. CNS Neurosci. Ther. 2020; 26 (6): 616-627. https://doi.org/10.1111/cns.13300
69. Henriques D., Moreira R., Schwamborn J., de Almeida P.L., Mendonça L.S. Successes and hurdles in stem cells application and production for brain transplantation. Front. Neurosci. 2019; 13: 1194. https://doi.org/10.3389/fnins.2019.01194
70. Gugliandolo A., Bramanti P., Mazzon E. Mesenchymal stem cells: a potential therapeutic approach for amyotrophic lateral sclerosis? Stem Cells Int. 2019; 2019: 3675627. https://doi.org/10.1155/2019/3675627
71. Fleifel D., Rahmoon M.A., AlOkda A., Nasr M., Elserafy M., El-Khamisy S.F. Recent advances in stem cells therapy: a focus on cancer, Parkinson’s and Alzheimer’s. J. Genet. Eng. Biotechnol. 2018; 16: 427-432. https://doi.org/10.1016/j.jgeb.2018.09.002
72. Scudellari M. How iPS cells changed the world. Nature. 2016; 534: 310-312. https://doi.org/10.1038/534310a
73. Goutman S.A., Savelieff M.G., Sakowski S.A., Feldman E.L. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin. Investig. Drugs. 2019; 28 (6): 525-543. https://doi.org/10.1080/13543784.2019.1627324
74. Tartaglione A.M., Popoli P., Calamandrei G. Regenerative medicine in Huntington’s disease: Strengths and weaknesses of preclinical studies. Neurosci. Biobehav. Rev. 2017; 77: 32-47. https://doi.org/10.1016/j.neubiorev.2017.02.017
75. Lee N.K., Yang J., Chang E.H., Park S.E., Lee J., Choi S.J., Oh W., Chang J.W., Na D.L. Intraarterially delivered mesenchymal stem cells are not detected in the brain parenchyma in an Alzheimer’s disease mouse model. PLoS One. 2016; 11 (5): e0155912. https://doi.org/10.1371/journal.pone.0155912
76. Cerri S., Greco R., Levandis G., Ghezzi C., Mangione A.S., Fuzzati-Armentero M.-T., Bonizzi A., Avanzini M.A., Maccario R., Blandini F. Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease’s disease, focusing on cell distribution and neuroprotective and behavioral effects. Stem Cells Transl. Med. 2015; 4 (9): 1073-1085. https://doi.org/10.5966/sctm.2015-0023
77. Alessandrini M., Preynat-Seauve O., de Bruin K., Pepper M.S. Stem cell therapy for neurological disorders. S. Afr. Med. J. 2019; 109 (8b): 70-77. https://doi.org/10.7196/SAMJ.2019.v109i8b.14009
78. Harris V.K., Stark J., Vyshkina T., Blackshear L., Joo G., Stefanova V., Sara G., Sadiq S.A. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in prgressive multiple sclerosis. EBioMedicine. 2018; 29: 23-30. https://doi.org/10.1016/j.ebiom.2018.02.002
79. Cuascut F.X., Hutton G.J. Stem cell-based therapies for multiple sclerosis: current perspectives. Biomedicines. 2019; 7 (2): 26. https://doi.org/10.3390/biomedicines7020026
80. Abramowski P., Krasemann S., Ernst T., Lange C., Ittrich H., Schweizer M., Zander A.R., Martin R., Fehse B. Mesenchymal stromal/stem cells do not ameliorate experimental autoimmune encephalomyelitis and are not detectable in the central nervous system of transplanted mice. Stem Cells Dev. 2016; 25 (15): 1134-1148. https://doi.org/10.1089/scd.2016.0020
81. Osborn T.M., Hallett P.J., Schumacher J.M., Isacson O. Advantages and recent developments of autologous cell therapy for Parkinson’s disease patients. Front. Cell. Neurosci. 2020; 14: 58. https://doi.org/10.3389/fncel.2020.00058
82. Новик А.А., Иванов Р.А., Шевченко Ю.Л. Клеточная терапия. М.: МИА, 2008. 240 c.
83. Новик А.А., Ионова Т.И., Иванов Р.А. Аутологичная трансплантация стволовых кроветворных клеток - новый метод лечения рассеянного склероза. СПб.: Береста, 2008. 52 c.
84. Мхеидзе Д.М., Гришина В.В., Мелкова К.Н. Заготовка гемопоэтических стволовых клеток: методические рекомендации. М.: Ин-т стволовых клеток человека, 2007.
85. Duncan T., Valenzuela M. Alzheimer’s disease, dementia, and stem cell therapy. Stem Cell Res. Ther. 2017; 8 (1): 111. https://doi.org/10.1186/s13287-017-0567-5
86. Kim H.J., Seo S.W., Chang J.W., Lee J.I., Kim C.H., Chin J., Choi S.J., Kwon H., Yun H.J., Lee J.M., Kim S.T., Choe Y.S., Lee K.H., Na D.L. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase 1 clinical trial. Alzheimers Dement. (NY). 2015; 1 (2): 95-102. https://doi.org/10.1016/j.trci.2015.06.007
87. Argibay B., Trekker J., Himmelreich U., Beiras A., Topete A., Taboada P., Pérez-Mato M., Vieites-Prado A., Iglesias-Rey R., Rivas J., Planas A.M., Sobrino T., Castillo J., Campos F. Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. Sci. Rep. 2017; 7: 40758. https://doi.org/10.1038/srep40758
88. Fernández-Susavila H., Bugallo-Casal A., Castillo J., Campos F. Adult stem cells and induced pluripotent stem cells for stroke treatment. Front. Neurol. 2019; 10: 908. https://doi.org/10.3389/fneur.2019.00908
89. Chrostek M.R., Fellows E.G., Crane A.T., Grande A.W., Low W.C. Efficacy of stem cell-based therapies for stroke. Brain Res. 2019; 1722: 146362. https://doi.org/10.1016/j.brainres.2019.146362
90. Krause M., Phan T.G., Ma H., Sobey C.G., Lim R. Cell-based therapies for stroke: are we there yet? Front. Neurol. 2019; 10: 656. https://doi.org/10.3389/fneur.2019.00656
91. Surugiu R., Olaru A., Hermann D.M., Glavan D., Catalin B., Popa-Wagner A. Recent advances in monoand combined stem cell therapies of stroke in animal models and humans. Int. J. Mol. Sci. 2019; 20 (23): 6029. https://doi.org/10.3390/ijms20236029
92. Borlongan C.V. Concise review: stem cell therapy for stroke patients: are we there yet? Stem Cells Transl. Med. 2019; 8 (9): 983-988. https://doi.org/10.1002/sctm.19-0076
93. Steinberg G.K., Kondziolka D., Wechsler L.R., Lunsford L.D., Kim A.S., Johnson J.N., Bates D., Poggio G., Case C., McGrogan M., Yankee E.W., Schwartz N.E. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J. Neurosurg. 2018; 1-11. https://doi.org/10.3171/2018.5.JNS173147
94. Yamazaki K., Kawabori M., Seki T., Houkin K. Clinical trials of stem cell treatment for spinal cord injury. Int. J. Mol. Sci. 2020; 21 (11): 3994. https://doi.org/10.3390/ijms21113994
95. Cofano F., Boido M., Monticelli M., Zenga F., Ducati A., Vercelli A., Garbossa D. Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int. J. Mol. Sci. 2019; 20 (11): 2698. https://doi.org/10.3390/ijms20112698
96. Cucurachi S., Tamis W.L., Vijver M.G., Peijnenburg W.J., Bolte J.F., de Snoo G.R. A review of the ecological effects of radiofrequency electromagnetic fields (RF-EMF). Environ. Int. 2013; 51: 116-140. https://doi.org/10.1016/j.envint.2012.10.009
97. Beers G.J. Biological effects of weak electromagnetic fields from 0 Hz to 200 MHz: a survey of the literature with special emphasis on possible magnetic resonance effects. Magn. Reson. Imaging. 1989; 7 (3): 309-331. https://doi.org/10.1016/0730-725x(89)90556-0
98. Tiwari S.S., Desai P.N. Unproven stem cell therapies in India: regulatory challenges and proposed paths forward. Cell Stem Cell. 2018; 23 (5): 649-652. https://doi.org/10.1016/j.stem.2018.10.007
99. Krimsky S. Stem cell dialogues: a philosophical and scientific inquiry into medical frontiers. New York: Columbia University Press, 2015. 239 р.
100. Пинаев Г.П. Проблемы и перспективы развития клеточных технологий. В кн.: Клеточные технологии для регенеративной медицины. Ред. Г.П. Пинаев, М.С. Богданова, А.М. Кольцова. СПб.: Политехн. ун-т, 2011; 8-24.
101. Knoepfler P. Stem cells: an insider’s guide. Singapore: World scientific, 2014. 368 p.
102. Jiang L., Dong B.H. Fraudsters operate and officialdom turns a blind eye: a proposal for controlling stem cell therapy in China. Med. Health Care Philos. 2016; 19 (3): 403-410. https://doi.org/10.1007/s11019-016-9692-7
103. Fujita M., Hatta T., Ozeki R., Akabayashi A. The current status of clinics providing private practice cell therapy in Japan. Regen. Med. 2016; 11 (1): 23-32. https://doi.org/10.2217/rme.15.64
104. Zarzeczny A., Clark M. Unproven stem cell-based interventions & physicians’ professional obligations; a qualitative study with medical regulatory authorities in Canada. BMC Med. Ethics. 2014; 15: 75. https://doi.org/10.1186/1472-6939-15-75
105. Amezcua L., Nelson F. Ethical considerations of patient-funded research for multiple sclerosis therapeutics. Neurotherapeutics. 2017; 14 (4): 945-951. https://doi.org/10.1007/s13311-017-0560-9
106. Konomi K., Tobita M., Kimura K., Sato D. New Japanese initiatives on stem cell therapies. Cell Stem Cell. 2015; 16 (4): 350-352. https://doi.org/10.1016/j.stem.2015.03.012
Рецензия
Для цитирования:
Яргин С.В. Проблемы клеточной терапии и стволовых клеток. Сибирский научный медицинский журнал. 2021;41(1):4-15. https://doi.org/10.18699/SSMJ20210101
For citation:
Jargin S.V. Some aspects of cell therapy and stem cells. Сибирский научный медицинский журнал. 2021;41(1):4-15. (In Russ.) https://doi.org/10.18699/SSMJ20210101
Просмотров:
917
ISSN 2410-2512 (Print)
ISSN 2410-2520 (Online)
ISSN 2410-2520 (Online)
Послать статью по эл. почте 